Results 121 to 130 of about 37,430 (216)

Successful Bailout Retrieval of an Active‐Fixation Atrial Leadless Pacemaker Following Suspected Tissue Entrapment During Repositioning

open access: yesJournal of Arrhythmia, Volume 42, Issue 5, October 2026.
(A) Unscrewing of AVEIR AR. (B) After unscrewing, the device appeared to be trapped with the stretched helix. (C) Successful retrieval was achieved by fully covering the device. (D) The retrieved device demonstrated the stretched helix. ABSTRACT An 81‐year‐old woman with a medical history of mechanical mitral valve replacement, Maze procedure, and ...
Toshiya Yoshida   +4 more
wiley   +1 more source

Hippo Pathway–YAP/TAZ Signaling: Molecular Mechanisms, Biological Function, Diseases, and Therapeutic Targets

open access: yesMedComm, Volume 7, Issue 10, October 2026.
The Hippo–YAP/TAZ–TEAD pathway integrates mechanical and biochemical cues to govern organ growth, regeneration, cancer, and fibrosis. This review dissects pathway physiology, TEAD structural pharmacology and ligandable pockets, and therapeutic strategies spanning palmitoylation‐pocket inhibitors, PROTAC degraders, and gene/RNA therapies, highlighting ...
Xiaodan Qu, Zhan‐you Wang
wiley   +1 more source

The Role of the Antidepressants in Managing Chemotherapy‐Induced Neuropathic Pain: A Systematic Review

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
From symptom relief to multimodal care: duloxetine and amitriptyline may reduce established CIPN‐related pain and provide a therapeutic foundation for future combination strategies. ABSTRACT Chemotherapy‐induced peripheral neuropathy (CIPN) is a prevalent and debilitating complication of cancer treatment, characterized by neuropathic pain, sensory ...
Rosamaria Caminiti   +13 more
wiley   +1 more source

Lenalidomide for the treatment of relapsed and refractory multiple myeloma

open access: yesCancer Management and Research, 2012
Niels WCJ van de Donk,1,2 Güllü Görgün,1 Richard WJ Groen,1,3 Jana Jakubikova,1 Constantine S Mitsiades,1 Teru Hideshima,1 Jacob Laubach,1 Inger S Nijhof,2 Reinier A Raymakers,2 Henk M Lokhorst,2 Paul G Richardson,1 ...
van de Donk NW   +11 more
doaj  

To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy

open access: yesEuropean Journal of Haematology, Volume 117, Issue 4, Page 750-766, October 2026.
ABSTRACT Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment.
Enrica Antonia Martino   +16 more
wiley   +1 more source

Lenalidomide-Induced Acute Interstitial Nephritis

open access: yes, 2010
The first case of biopsy-proven lenalidomide-induced acute interstitial nephritis is presented.
Danniele G. Holanda   +4 more
core   +1 more source

Extranodal Marginal Zone Lymphoma: Integrating Etiology, Microenvironment, and Genetics Into Clinical Decision‐Making

open access: yesEuropean Journal of Haematology, Volume 117, Issue 4, Page 849-863, October 2026.
ABSTRACT Extranodal marginal zone lymphoma (EMZL) represents a unique paradigm among indolent B‐cell neoplasms, in which lymphomagenesis is frequently driven by chronic antigenic stimulation within tissue‐specific microenvironments. Persistent infectious or autoimmune triggers promote the development of ectopic lymphoid tissue and sustain B‐cell ...
Mamdouh Skafi   +15 more
wiley   +1 more source

Therapeutic Benefits of Lenalidomide in Hematological Malignancies

open access: yes, 2019
Lenalidomide is an immunomodulatory agent, which has action against most of the hematological malignancies. Apart from its immunomodulation, it has other properties such as antiproliferation and antiangiogenesis.
Durai Mavalavan Vasudevan Manimoliyan   +1 more
core   +1 more source

Longitudinal assessments of MRD in high‐risk newly diagnosed transplant‐ineligible multiple myeloma in the BENEFIT study (IFM2020‐05)

open access: yes
HemaSphere, Volume 10, Issue 10, October 2026.
Jill Corre   +53 more
wiley   +1 more source

Clinical management of clonal hematopoiesis

open access: yesCancer, Volume 132, Issue 18, 15 September 2026.
ABSTRACT Clonal hematopoiesis, particularly clonal hematopoiesis of indeterminate potential and clonal cytopenia of undetermined significance, is an age‐related premalignant condition characterized by the expansion of hematopoietic clones carrying somatic mutations.
Kelly S. Chien   +1 more
wiley   +1 more source

Home - About - Disclaimer - Privacy